23 January 2017 - Novelion Therapeutics today announced that the EMA has accepted for review the marketing authorisation application for metreleptin as replacement therapy to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy and in a subset of patients with partial lipodystrophy. 

The MAA was filed in December 2016. An opinion from the Committee for Medicinal Products for Human Use is expected in December of 2017, and decision is expected in the first quarter of 2018.

Read Novelion Therapeutics press release